



ALK  
Investor Relations Department  
BÃ,ge Alle 6-8  
Horsholm DK-2970  
Denmark

Visit IR website [↗](#)  
Sign-up for Email alerts [↗](#)

#### OMX: ALKB

Last Trade:	986.00
Trade Time:	4:59 PM ET Sep 25, 2017
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	839.00 - 1133.00
Volume	1,155,200

Stock information is provided by eSignal,  
stock charts provided by EDGAR Online.  
Stock data is delayed approximately 20  
minutes.

## Company Profile

ALK is the world leader in allergy vaccination (immunotherapy). It is the goal of ALK to increase the awareness of the company and its activities through a structured, ongoing, timely and balanced dialogue with investors, shareholders and other stakeholders. It is also a company goal to secure the liquidity of the company's shares and to generate reasonable, long-term returns to shareholders through share price increases and dividends.... [\(more\)](#)

## Company releases [\[ View all \]](#)

*Sep 21, 2017*

[ALK acts on French injunction by accelerating investments in its quality system at the French manufacturing facility](#)

*Sep 14, 2017*

[Successful Phase III trial for ALK's tree allergy SLIT-tablet](#)

*Sep 4, 2017*

[Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff](#)

*Aug 21, 2017*

[ALK to accelerate launches of ODACTRA™ in the USA / ACARIZAX® in Canada](#)

*Aug 16, 2017*

[Six-month interim report \(Q2\) 2017](#)

## Upcoming Events [\[ View all \]](#)

*Nov 10, 2017*

[Nine-month interim report \(Q3\) 2017](#)